RBN-2397: A potent and selective small molecule inhibitor ...
Transcript of RBN-2397: A potent and selective small molecule inhibitor ...
0
• Joe Gozgit• Ribon Therapeutics
RBN-2397: A potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells
1
Disclosure Statement• I am an employee and shareholder of Ribon Therapeutics
2
Targeting PARP7 to Restore Tumor-Derived Type I Signaling is a Novel Therapeutic Strategy in Cancer
• Engaging cytosolic nucleic acid sensing and the Type I interferon (IFN) response is an emerging therapeutic strategy
• Stimulate production of cytokines to promote an adaptive immune response
• Currently, most approaches involve agonistic modulation of the tumor microenvironment
• PARP7 is a monoPARP regulated by cancer relevant stresses
• Amplified in cancers with strong smoking association
• Acts as a “brake” on cytosolic nucleic acid sensing and suppresses Type I IFN signaling
Targeting a negative regulator of tumor-produced Type I IFN is a novel therapeutic strategy
PARP7 acts as a fundamental regulator of intrinsic stress support pathways and is a novel tumor
vulnerability in cancer cells
3
Aberrant nucleic acids can be detected by various sensing mechanisms including cGAS/STING and RIG-I
PARP7 Acts as a Brake on Cytosolic Nucleic Acid Sensing and the Type I IFN Response
DO NOT POST
Suppression of IFN-β by PARP7
Overexpression of PARP7 suppresses IFN-βresponse to dsDNA
Synthetic dsDNA
PARP7 has been reported to negatively regulate the Type I response by interacting with TBK1 during viral
infection (Yamada et al., 2016)
HEK293T cells transfected with PARP7 treated with synthetic double stranded (ds)-DNA for 24 hours
4
RBN-2397 is a Potent and Selective Inhibitor of PARP7
• RBN-2397 is a potent inhibitor of PARP7• Binds to PARP7 in the NAD+ binding pocket
with key interactions in adenosine sub-pocket driving potency and selectivity
• Sub-nanomolar biochemical activity
• RBN-2397 displays selectivity to PARP7• >50-fold selective vs. PARP family• No inhibition in kinase panel (1 µM)
• Drug-like properties support oral dosing in humans
• First in human Phase I multi-center clinical trial is underway (NCT04053673)
NNH
F3CO
HNO N
O
N N
NCF3
Structure of RBN-2397
Co-crystal structure of RBN-2397 bound to PARP12/7
PARP12 was used as a surrogate for PARP7. Four labeled residues were mutated from PARP12 to match the PARP7 sequence
DO NOT POST
5
0.0001 0.001 0.01 0.1 1 10 1000
20
40
60
80
100
120
RBN-2397 (µM)
Perc
ent I
nhib
ition
of
MAR
or P
AR
PARP7 (MAR)IC50 = 0.002 µM
PARP1 (PAR)IC50 = 0.6 µM
0.0001 0.001 0.01 0.1 1 10 1000
20
40
60
80
100
120
Niraparib (µM)
Perc
ent I
nhib
ition
of
MAR
or P
AR
PARP1 (PAR)IC50 = 0.003 µM
PARP7 (MAR)IC50 = 2.6 µM
RBN-2397 Potently and Selectively Inhibits PARP7-Dependent Activity Compared to PARP1
DO NOT POST
Vyas et al., 2013
• PARPs regulate their cellular function by modifying target proteins with ADP-ribose
• PolyPARPs (e.g., PARP1) attach polymers of ADP-ribose units (PARylation)
• MonoPARPs (e.g., PARP7) modify proteins with a single unit of ADP-ribose (MARylation)
PARP family consists of 17 members:2 subclasses based on catalytic activity
RBN-2397 potently inhibits MARylation with a 300-fold window over PARylation
PARP1-H2O2 activated Hela cells (PAR)PARP7-overexpressing SK-MES-1 cells (MAR)
PARP1 inhibitor: Niraparib
PARP7 inhibitor: RBN-2397
Lu et al., 2019
PARMAR
24-hour treatment
6
RBN-2397 Restores Cytosolic Nucleic Acid Sensing in the Mouse CT26 Cancer Cell Line
Selective induction of CXCL10
RBN-2397 restores Type I IFN response in CT26 cells
Induction of pSTAT1
Restoration of Type I IFN response is measured by an increase in STAT1 phosphorylation and interferon
stimulated genes (ISGs)
PARP7 inhibition “releases the brake” on cytosolic nucleic acid sensing and induces Type I IFNs
e.g. CXCL10
DO NOT POST
0 12 37 111 333 10000
2
4
6
8
CXCL
10 m
RNA
FC (R
elat
ive
to D
MSO
)
RBN-2397Inactive analogOlaparib
Compound (nM) 24-hour treatment
7
RBN-2397 Restores Cytosolic Nucleic Acid Sensing Dependent on Pattern Recognition Receptor Signaling
RBN-2397 restores Type I IFN signaling through pattern recognition receptor pathway
Pharmacological inhibitors used to investigate the role of PARP7 in suppressing Type I IFNs
e.g. CXCL10
DO NOT POST
XX
X
JAKTBK1 STING
BX795: TBK1 inhibitorRuxolitinib: JAK inhibitorC-178: STING inhibitor
Blockade of:
24-hour treatment
8
RBN-2397 Induces Tumor-Specific Adaptive Immune Memory in CT26 Syngeneic Model with Durable Complete Responses
CT26 re-challenge 4T1 re-challenge
• Once daily oral dosing of RBN-2397 in CT26 tumor-bearing BALB/c mice
• Tumor-free mice were monitored for 60 days
• Tumor-free mice re-challenged with CT26 and subsequently 4T1 cells
• All tumor-free mice rejected CT26 cells but not 4T1, demonstrating induction of tumor-specific adaptive immune memory
Primary Efficacy: RBN-2397 induces durable regressions Re-challenge of tumor-free mice: Rejection of CT26 cells
TF: Tumor free miceAll groups co-dosed with ABT
0 4 8 12 16 20 240
500
1000
1500
2000
Time post tumor re-challenge (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Naive miceTumor free mice
0 4 8 12 16 20 240
200
400
600
800
1000
Time post tumor re-challenge (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Naive miceTumor free mice
DO NOT POST
0 20 40 60 80 100 1200
500
1000
1500
2000
2500
3000Vehicle
Time (d)
Tum
or v
olum
e (m
m3 )
0 20 40 60 80 100 1200
500
1000
1500
2000
2500
3000RBN-2397 3 mg/kg
Time (d)
Tum
or v
olum
e (m
m3 )
0 20 40 60 80 100 1200
500
1000
1500
2000
2500
3000RBN-2397 10 mg/kg
Time (d)
Tum
or v
olum
e (m
m3 )
0 20 40 60 80 100 1200
500
1000
1500
2000
2500
3000RBN-2397 30 mg/kg
Time (d)
Tum
or v
olum
e (m
m3 )
0 20 40 60 80 100 1200
500
1000
1500
2000
2500
3000RBN-2397 100 mg/kg
Time (d)
Tum
or v
olum
e (m
m3 )
5 TF4 TF
Dosing period Dosing period Dosing period
Dosing period Dosing period
9
0 5 10 15 20 25 300
500
1000
1500
2000
2500
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Vehicle3 mg/kg10 mg/kg30 mg/kg100 mg/kg
0 5 10 15 20 25 300
500
1000
1500
2000
2500
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Vehicle30 mg/kg100 mg/kg
CT26 mouse model Innate immune cells
Adaptive immune cells
Mouse Strain
RBN-2397Efficacy NK Mac B T DC
BALB/cTumor
regression + + + + +
NOG
~50% TGI - -a - - -a
Adaptive Immune Response is Indispensable for RBN-2397 Antitumor Activity
RBN-2397 shows substantially reduced activity in CT26 tumor-bearing immunodeficient mice
Characterization of immune cell populations present in BALB/c and NOG mice
+: Present; -: Absenta: Reduced macrophage and dendritic cell function
NOG: Immunodeficient
All groups co-dosed with ABT
9 tumor-free mice
BALB/c: Immunocompetent
10
CD4CD8 NK
0
500
1000
Subset
Cells
/µl
Isotype controlAnti-CD4Anti-CD8Anti-asialoGM1Anti-CD4 + anti-CD8 + anti-asialoGM1
CD4 CD8 NK0
500000
1000000
1500000
Subset
Cel
ls/g
m o
f tum
or
Isotype controlAnti-CD4 + anti-CD8 + anti-asialoGM1
Robust Depletion of Immune Cell Populations in CT26 Tumor-Bearing Mice
-10 1 10 20 30 Days
Tumor implantation
Administration of blocking antibodies to deplete CD4, CD8
and NK cells
RBN-2397 dosing
Efficacy readout
Monitor immune cell populations
BALB/c
Scheme for immune cell depletion in CT26-tumor-bearing BALB/c mice
Specific depletion of immune cell populations
Blood absolute counts
Tumor absolute counts
11
0 5 10 15 20 25 30 350
1000
2000
3000
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Vehicle + Isotype controlRBN-2397 + isotype controlanti-CD4RBN-2397 + anti-CD4
0 5 10 15 20 25 30 350
1000
2000
3000
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Vehicle + Isotype controlRBN-2397 + isotype controlanti-CD8RBN-2397 + anti-CD8
0 5 10 15 20 25 30 350
1000
2000
3000
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
Vehicle + Isotype controlRBN-2397 + isotype controlanti-asialoGM1RBN-2397 + anti-asialoGM1
0 5 10 15 20 25 30 350
1000
2000
3000
Time (d)M
ean
Tum
or V
olum
e (m
m3 )
Vehicle + Isotype controlRBN-2397 + isotype controlanti-CD4 + anti-CD8 + anti-asialoGM1RBN-2397 + anti-CD4 + anti-CD8 + anti-asialoGM1
CD8 T Cells Are Essential for the Antitumor Immunity Induced by RBN-2397 in the CT26 Syngeneic Model
CD4 T cell depletion had no effect on antitumor activity
NK cell depletion had no effect on antitumor activity
CD8 T cell depletion attenuated antitumor activity
Triple depletion was not different than CD8 T cell single depletion
All groups co-dosed with ABT
12
RBN-2397 Induces Type I IFN Signaling and Enhances Immune Markers in CT26 Tumors
Increase in GrzB on CD8 T cells
RBN-2397 shows dose-dependent effects on PD markers in CT26 tumors
RBN-2397 enhances antigen presentation and T cell activation in tumor-infiltrating immune cells
Increase in MHCII on DC1 cells Increase in CD86 on DC1 cells
Vehicle RBN-2397 0
20000
40000
60000
80000
100000
GZM
B M
FI D
ay 1
2(o
n CD
8+ c
ells
)
P < 0.0001
Vehicle RBN-2397 0
50000
100000
150000
200000
MH
CII M
FI D
ay 3
(on
DC1
cells
)
P = 0.0243
CT26 tumor-bearing mice administered as single oral dose.All groups co-dosed with ABT
CT26 tumor-bearing mice dosed with RBN-2397 500 mg/kg. Tumors collected on days 3, 6 & 12.
DO NOT POST
IFN-β CXCL10 IFIT1 MX10
2
4
6
8
10
mRN
A Le
vels
(Fol
d Ch
ange
)
Vehicle10 mg/kg30 mg/kg100 mg/kg
Gene
13
0 4 8 12 16 20 24 28 32 36 400
500
1000
1500
2000
2500
3000 VehicleRBN-2397 100 mg/kg
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
0 4 8 12 16 20 24 28 32 36 400
500
1000
1500
2000
2500
3000
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 ) VehicleRBN-2397 100 mg/kg
0 4 8 12 16 20 24 28 32 36 400
500
1000
1500
2000
2500
3000
Time (d)
Mea
n Tu
mor
Vol
ume
(mm
3 )
VehicleRBN-2397 100 mg/kgRBN-2397 100 mg/kg + Anti-IFNAR1
• Ablation of tumor TBK1 nearly eliminates the antitumor activity of RBN-2397
• Tumor-produced IFN-β is the source of the innate immune activation and crucial for antitumor activity
• Blockade of tumor and host IFNAR1 signaling prevents the antitumor activity of RBN-2397
• Suggests contribution of immune system through activation of IFN signaling in immune cells by tumor-produced IFN-β
All groups co-dosed with ABT
Type I IFN Produced by Tumors in Response to RBN-2397 Plays a Major Role in the Development of Durable Antitumor Immunity in CT26 Model
DO NOT POST
Tumor TBK1
Tumor + Host IFNAR1
Tumor IFNAR1
CT26 wild type CT26 TBK1 KO CT26 IFNAR1 KO + anti-IFNAR1
14
RBN-2397 is the First Potent and Selective PARP7 Inhibitor to Enter Clinical Development
• Targeting PARP7 to restore tumor-derived Type I signaling is a novel therapeutic strategy in cancer
• Inhibition of PARP7 induces antitumor immunity dependent on tumor-produced Type I IFN and CD8 T cells
• RBN-2397 is the first agent targeting this cancer vulnerability to enter clinical development
Complete regressions and antitumor immunity as a single agent
IFNUncloaks the tumor cells and recruits immune cells
DO NOT POST
PARP7 acts as a “brake” on cytosolic nucleic acid sensing and suppresses the Type I IFN response
Ribon PARP7 abstracts at AACR 2021#381: PARP7 expression in cancer#1021: PARP7 inhibitor mechanism of action studies
15
Acknowledgements
Victoria RichonAndy SantospagoLaurie SchenkelRichard SchroederPrashant ShambharkarJeff SongTad StewartKerren SwingerLuke UtleyZacharenia VarsamisMelissa VasbinderTim WigleJodie Wong
Ryan AboEllen BambergDanielle BlackwellRichard BushellAnne CheungW. David ChurchLisa ClearyDavid CordoBryan DorseyJennifer DowningJoseph GozgitLinette GreyBin GuiHeike KeilhackPeter KimDanielle KnightKaiko Kunii
Team Ribon:Kevin KuntzKristy Kuplast-BarrJenkins LemeraChang LiuAlvin LuAhmed MadyChristina MajerKristen McEachernMaegan MikulaElena MinissaleJason MoJennifer MolinaSunaina NayakMario NiepelSudha ParasuramanNicholas PerlYue Ren
Paul ChangLee KrausTimothy Mitchison
James AudiaLarry LaskyPatricia Rao
Founders and Advisors:
DO NOT POST